My SciELO
Services on Demand
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista Cubana de Hematología, Inmunología y Hemoterapia
On-line version ISSN 1561-2996
Abstract
CALDERIN MIRANDA, José Miguel; DE CASTRO SUAREZ, Niurys and FERNANDEZ, Gledys Reynaldo. Indolent non-Hodgkin's lymphomas and anti-CD20 therapy: a literature review. Rev Cubana Hematol Inmunol Hemoter [online]. 2022, vol.38, n.2 Epub June 01, 2022. ISSN 1561-2996.
Introduction:
Indolent non-Hodgkin's lymphomas are notable for the challenge they pose from a therapeutic point of view. The introduction of rituximab, a monoclonal antibody that binds to the CD20 antigen of the B-lymphocyte membrane, revolutionized treatments up to that time and opened the way for the development of other anti-CD20 monoclonal antibodies.
Objective:
To describe the general characteristics of indolent non-Hodgkin's lymphomas and anti-CD20 monoclonal antibodies, as well as the role of anti-CD20 therapy in these diseases.
Methods:
A review of the literature published in the last 20 years, available in the repositories: Scielo, Scopus, Pubmed/Medline, Science Direct and Mediagraphic, was performed. Thirty-five papers were used to prepare this manuscript, 80% of which corresponded to the last 5 years.
Conclusions:
Strong scientific evidence, accumulated over the last two decades, supports the clinical use of anti-CD20 monoclonal antibodies in the treatment of indolent non-Hodgkin's lymphomas. The effective use of these drugs as single agents or in combination with chemotherapy demonstrates their therapeutic versatility.
Keywords : indolent non-Hodgkin's lymphoma; CD20; monoclonal antibody; rituximab; biosimilar; pharmacokinetics; pharmacodynamics.